본문바로가기
  • ABOUT US
  • Who we are

ABOUT US

Diversified pharmaceutical company with divisions
for novel medicines and complex generics

Who we are

KYOJIN PARKCEO

  • Co-founder & Partner at MedCI LLC (Santa Clara, CA, USA)
    (Helped to execute over 30 cross-border licensing deals in innovative drugs)
  • Univ. of Michigan Hospital Dean’s Office Director, International Patient Center, Trinity Health System Business Consultant
  • MBA, University of Michigan

WEONBIN IMPresident/CTO

  • Dong-A ST Vice President of Research Center
  • Tedizolid(Sivextro®): FDA, EMA Approval and Sales(Merck); R&D on Immuno-oncology, CNS, Digestive and Metabolic diseases
  • 20 patents, Awarded the highest patented technology in 2010, Awarded Korea New Drug Award in 2015
  • PhD, A-Jou University, Molecular Science and Technology
  • SUNNY (WON SUN) HANCOO

    • Director, Business Development: GPCR, Amyloid Solution, Dong-A ST
    • Project Manager, Swiss Embassy in Korea, Chicago Univ., Yale Univ. Tech Transfer Center
    • Post-Doc., Yale Univ. Cellular, & Molecular Physiology
    • PhD, Pharmacology & Cell Biology from Yonsei University
  • MANISH SINGHAL CBO

    • Co-Founder & Partner at MedCI LLC (Santa Clara, CA, USA)
    • Practicing in internal medicine at Stanford University Hospital
    • Director, Marketing, Xolan Technologies
    • MD, University of Texas at San Antonio
    • MBA, University of Michigan
  • SO-YOUNG EUNCDO

    • Chief of Business Center, R&D, AprilBio
    • Senior Research Scientist, Immuno-Oncology, MOGAM Institute
    • Post-Doc., La Jolla Institute for Allergy and Immunology
    • PhD, Immunology from University of North Carolina at Chapel Hill
  • EOK PARKDevelopment Div / Sr.Director

    • Director, Research & Development, QuBESTBio/
      MitoImmune Therapeutics
    • Senior Researcher, Life Sciences New Drug Research Center, LG Chem
    • MS, Virology from Sogang University
  • BYONGKEOL MINManager

    • Early discovery to lead optimization studies leading to candidate selection
    • In vitro/in vivo POC studies
    • PhD, Metabolic disease&Immunology from Kyungpook National University
  • TAEWON KIMManager

    • Establish the development plan of ArborMed's overall pipelines
    • Design and manage research projects with contract organizations for IND
    • PhD,University of Wisconsin-Madison, Molecular and Environmental Toxicology
  • SUMIN SEONG Assistant manager

    • Manage Accounting, HR, General Affairs
  • DONGEUN IMAssistant manager

    • Business development/Patent portfolio management